galunisertib   Click here for help

GtoPdb Ligand ID: 7797

Synonyms: inhibitor 15d [PMID: 18314943] | LY-2157299 | LY2157299
Compound class: Synthetic organic
Comment: Galunisertib is a first-in-class investigational inhibitor of the receptor tyrosine kinase, growth factor-β receptor type I (TGFβRI) [1-2]. It is being evaluated as a novel anticancer agent.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 5
Hydrogen bond donors 1
Rotatable bonds 3
Topological polar surface area 86.69
Molecular weight 369.16
XLogP 2.67
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES Cc1cccc(n1)c1nn2c(c1c1ccnc3c1cc(cc3)C(=O)N)CCC2
Isomeric SMILES Cc1cccc(n1)c1nn2c(c1c1ccnc3c1cc(cc3)C(=O)N)CCC2
InChI InChI=1S/C22H19N5O/c1-13-4-2-5-18(25-13)21-20(19-6-3-11-27(19)26-21)15-9-10-24-17-8-7-14(22(23)28)12-16(15)17/h2,4-5,7-10,12H,3,6,11H2,1H3,(H2,23,28)
No information available.
Summary of Clinical Use Click here for help
Galunisertib is being evaluated in Phase 3 clinical trials for the treatment of various solid tumours (including those of the liver, prostate, pancreas and brain) as well as myelodysplastic syndromes. Click here to link to a full list of galunisertib trials registered with